Restoring immune defenses via lymphotoxin signaling: Lessons from cytomegalovirus

Immunologic Research

Volumn 34, Issue 3, 2006, Pages 243-253

  Banks, Theresa A ^a,b   Rickert, Sandra ^c   Ware, Carl F ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Allimmune LLC   (United States)

^c Gemini Science   (United States)

Author keywords

Antibody immunotherapy; Cytomegalovirus; Herpesvirus; Interferons; Lymphotoxin beta receptor

Indexed keywords

ADALIMUMAB; ANTIVIRUS AGENT; CIDOFOVIR; CYTOKINE; ETANERCEPT; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; INFLIXIMAB; INTERFERON; INTERLEUKIN 2; LENERCEPT; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN BETA RECEPTOR ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ADVERSE DRUG REACTION; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HERPES VIRUS; HOST RESISTANCE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINITIS; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, NATURAL; INFANT, NEWBORN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOTOXIN-ALPHA; MICE; PREGNANCY;

EID: 33746891509     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:34:3:243     Document Type: Review

References (47)

1. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104:487-501.
2. Bodmer JL, Schneider P, Tschopp J: The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27:19-26.
3. De Togni P, Goellner J, Ruddle NH, et al: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994; 264:703-706.
4. Ware CF: Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005; 23:787-819.
5. Mauri DN, Ebner R, Montgomery RI, et al: LIGHT, a new member of the TNF superfamily and lymphotoxin a are ligands for herpesvirus entry mediator. Immunity 1998; 8:21-30.
6. Sedy JR, Gavrieli M, Potter KG, et al: B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6:90-98.
7. Cheung TC, Humphreys IR, Potter KG, et al: Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci USA 2005; 102:13218-13223.
8. Ansel KM, Ngo VN, Hyman PL, et al: A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406:309-314.
9. Luther SA, Bidgol A, Hargreaves DC, et al: Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002; 169:424-433.
10. Murphy M, Walter BN, Pike-Nobile L, et al: Expression of the lymphotoxin β-receptor on follicular stromal cells in human lymphoid tissue. Cell Death Differentiation 1998; 5:497-505.
11. Stopfer P, Obermeier F, Dunger N, et al: Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis. Clin Exp Immunol 2004; 136:21-29.
12. Cohavy O, Zhou J, Granger SW, Ware CF, Targan SR: LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine. J Immunol 2004;173:251-258.
13. Morel Y, Schiano de Colella JM, Harrop J, et al: Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000; 165:4397-4404.
14. Kwon BS, Tan KB, Ni J, et al: A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997; 272:14272-14276.
15. Wu Q, Sun Y, Wang J, et al: Signal via lymphotoxin-beta R on bone marrow stromal cells is required for an early checkpoint of NK cell development. J Immunol 2001; 166:1684-1689.
16. Elewaut D, Brossay L, Santee SM, et al: Membrane lymphotoxin is required early in ontogeny for development of different subpopulations of NK T cells. J Immunol 2000; 165:671-679.
17. Wu Q, Wang Y, Wang J, Hedgeman EO, Browning JL, Fu Y-X: The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissue. J Exp Med 1999; 190:629-638.
18. Abe K,Yarovinsky FO,Murakami T, et al: Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo. Blood 2003; 101:1477-1483.
19. Dejardin E, Droin NM, Delhase M, et al: The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17:525-535.
20. Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX: Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol 2005; 175:1295-1300.
21. Benedict CA, Banks TA, Ware CF: Death and survival: viral regulation of TNF signaling pathways. Curr Opin Immunol 2003; 15:59-65.
22. Spahn TW, Eugster HP, Fontana A, Domschke W, Kucharzik T: Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway. Infect Immun 2005; 73:7077-7088.
23. Benedict CA, Banks TA, Senderowicz L, et al: Lymphotoxins and cytomegalovirus cooperatively induce interferon-β, establishing host-virus détente. Immunity 2001; 15:617-626.
24. Banks TA, Rickert S, Benedict CA, et al: A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol 2005; 174:7217-7225.
25. Williams-Abbott L, Walter BN, Cheung T, Goh CR, Porter AG, Ware CF: The lymphotoxin-α (LTα) subunit is essential for the assembly, but not receptor specificity, of the membrane-anchored LTα1β2 heterotrimeric ligand. J Biol Chem 1997; 272: 19451-19456.
26. Rooney IA, Butrovich KD, Glass AA, et al: The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000; 275:14307-14315.
27. Singh N: Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006; 35:474-477.
28. Vancikova Z, Dvorak P: Cytomegalovirus infection in immunocompetent and immunocompromised individuals - a review. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1:179-187.
29. Grahame-Clarke C: Human cytomegalovirus, endothelial function and atherosclerosis. Herpes 2005; 12:42-45.
30. Revello MG, Gerna G: Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. J Clin Virol 2004; 29:71-83.
31. Gilbert C, Boivin G: Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-883.
32. Baldanti F, Lurain N, Gerna G: Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 2004; 65:403-409.
33. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF: Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. AntimicrobAgents Chemother 1996; 40:2004-2011.
34. Schleiss MR, Heineman TC: Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005; 4:381-406.
35. Hakki M, Riddell SR, Storek J, et al: Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102:3060-3067.
36. Fries BC, Riddell SR, Kim HW, et al: Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. Biol Blood Marrow Transplant 2005; 11:136-148.
37. Tartour E, Mathiot C, Fridman WH: Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46:473-484.
38. de Vries EG, Timmer T, Mulder NH, et al: Modulation of death receptor pathways in oncology. Drugs Today (Barc) 2003; 39 Suppl C:95-109.
39. Santoro A, Canova C: Anemia and erythropoietin treatment in chronic kidney diseases. Minerva Urol Nefrol 2005; 57:23-31.
40. Lyman GH: Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005; 3:557-571.
41. Courtney LP, Phelps JL, Karavodin LM: An anti-IL-2 antibody increases serum half-life and improves antitumor efficacy of human recombinant interleukin-2. Immunopharmacology 1994; 28:223-232.
42. Bonnet D, Schmaltz AA, Feltes TF: Infection by the respiratory syncytial virus in infants and young children at high risk. Cardiol Young 2005; 15:256-265.
43. Knight DM, Trinh H, Le J, et al: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-1453.
44. Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-1561.
45. Sarawar SR, Lee BJ, Reiter SK, Schoenberger SP: Stimulation via CD40 can substitute for CD4 T cell function in preventing reactivation of a latent herpesvirus. Proc Natl Acad Sci USA 2001; 98:6325-6329.
46. Browning JL, Miatkowski K, Sizing I, et al: Signalling through the lymphotoxin-b receptor induces the death of some adenocarcinoma tumor lines. J Exp Med 1996; 183:867-878.
47. Soriano V, Martin-Carbonero L, Maida I, Garcia-Samaniego J, Nunez M: New paradigms in the management of HIV and hepatitis C virus coinfection. Curr Opin Infect Dis 2005; 18:550-560.